Revolutionizing Combination Selection Processes to Optimize Response Rates, Effectiveness & Safety
A Case Study Based Look at IO Combinations in the Context of the Cancer Immunity Cycle

Expert Speakers Including:

Jonathan Zalevsky
Senior Vice President, Research and Chief Scientific Officer
NEKTAR Therapeutics

Beth Trehu
Chief Medical Officer
Jounce Therapeutics

Raphael Clynes
Vice President of Translational Biology
Xencor

Patrick Holder
Protein Chemistry Scientist
Genentech

Jochem Gokelmeijer
Associate Director
Bristol-Myers Squibb

Catherine Sabatos-Peyton
Director
Novartis

Osama Rahma
Assistant Professor
Dana-Farber Cancer Institute

Mithun Khattar
Scientist & Immuno-Oncology Lead
Takeda

Paul Moore
Vice President - Cell Biology & Immunology
MacroGenics

Partners:

Tel: +1 617 455 4188   Mail: info@hansonwade.com
Immune Checkpoint Inhibitors   @ici_checkpoint
Increasing Effectiveness and Safety of IO Combinations

This industry-led meeting will focus on how checkpoint combinations can impact every stage of the cancer immunity cycle; enhancing patient outcomes.

The unique format of the agenda offers a complete perspective of the effects of adaptive and innate immune components on combination success. Appreciate insights on the latest data on how drug developers are targeting of immune checkpoints, myeloid cells, cytokines, stromal cells, STING and kinase pathways such as Wnt & PI3K.

Breaking down these case-studies gives the opportunity to take un-pick specific preclinical, translational and clinical challenges. Bringing forward new ideas and concepts that you can build into your combination rationale. Stop taking shots in the dark, and start formulating calculated, precise studies that will yield results and true clinical value.

An Unparalleled Depth of Insights

1. Improve your combination rationale with a greater mechanistic understanding of the cancer immunity cycle and how combinations work within it.

2. Learn how Nektar Therapeutics supercharge the tumor microenvironment to optimize the effectiveness of checkpoint modulators through the use of cytokines.

3. Hear how Jounce Therapeutics reverse translated their ICOS-containing combination when it didn’t perform as expected to better inform future decision making.

4. Take apart the current approaches to target identification from biological and protein chemistry perspectives to find a faster, more efficient path to preclinical testing with a discussion between panelists from Genentech, Novartis and FusionBio.

5. Predict and plan for future roadblocks to development through our interactive workshops on preclinical development of IO combinations and maximizing the anti-tumor capability of the innate immune system.

Hear What Previous Attendees Have To Say

“Great meeting, very informative, great to see what other companies are working on in the field of cancer immunotherapy”
Genentech

“This conference was of outstanding value. First class presentations, great opportunity for networking and perfect logistics”
AstraZeneca

“Great opportunity for discussions between large pharma, small start ups, academia and regulatory authorities”
Merck
YOUR EXPERT SPEAKERS

John M. Burke
Co-Founder, President, and Chief Executive Officer
Applied Biomath

Amy-Jo Casbon
Immunotherapy & Oncology Scientist
Amgen Inc.

Raphael Clynes
Vice President of Translational Biology
Xencor

Viviana Cremasco
Investigator
Novartis

Jonathan Zalevsky
Senior Vice President, Research and Chief Scientific Officer
NEKTAR Therapeutics

Cedric Dos Santos
Principal Scientist Heme, Oncology, Clinical Biomarkers & Therapeutic Areas Lead
Amgen Inc.

Hans Van Eenemann
Executive Vice President Antibody Research and Site Head
Aduro Biotech

Shanthi Ganesh
Associate Director
Dicerna

Christelle Johnson
Senior Field Applications Scientist
Personalis

Jochem Gokemeijer
Associate Director
Bristol-Myers Squibb

Jeremy Graff
Chief Scientific Officer
Biothera

Patrick Holder
Protein Chemistry Scientist
Genentech

Mithun Khattar
Scientist & Immuno-Oncology Lead
Takeda

Paul Moore
Vice President - Cell Biology & Immunology
MacroGenics

Bruno Osterwalder
BO Consulting

Mark Paris
Director, Translational Applications Biopharma Business Development
Mitra Biotech Inc.

Weiyi Peng
Assistant Professor
University of Houston

Osama Rahma
Assistant Professor
Dana-Farber Cancer Institute

Paul Rennert
President and Chief Scientific Officer
Aleta Biotherapeutics

Catherine Sabatos-Peyton
Director
Novartis

Beth Trehu
Chief Medical Officer
Jounce Therapeutics

Shanthi Ganesh
Assistant Professor
University of Houston

Weiyi Peng
Assistant Professor
University of Houston

Osama Rahma
Assistant Professor
Dana-Farber Cancer Institute

Mark Yore
Manager of Corporate Development
Jounce Therapeutics

Sarah McWhirter
Director - Sting Program
Aduro Biotech

Mark Poznansky
Director, Vaccine and Immunotherapy Center (VIC), Massachusetts General Hospital (MGH) & Associate Professor
Harvard Medical School

Mark Paris
Director, Translational Applications Biopharma Business Development
Mitra Biotech Inc.

Weiyi Peng
Assistant Professor
University of Houston

Osama Rahma
Assistant Professor
Dana-Farber Cancer Institute

Paul Rennert
President and Chief Scientific Officer
Aleta Biotherapeutics

Catherine Sabatos-Peyton
Director
Novartis

Beth Trehu
Chief Medical Officer
Jounce Therapeutics

Shanthi Ganesh
Assistant Professor
University of Houston

Weiyi Peng
Assistant Professor
University of Houston

Osama Rahma
Assistant Professor
Dana-Farber Cancer Institute

Mark Yore
Manager of Corporate Development
Jounce Therapeutics

Sarah McWhirter
Director - Sting Program
Aduro Biotech

Mark Poznansky
Director, Vaccine and Immunotherapy Center (VIC), Massachusetts General Hospital (MGH) & Associate Professor
Harvard Medical School

Mark Paris
Director, Translational Applications Biopharma Business Development
Mitra Biotech Inc.

Weiyi Peng
Assistant Professor
University of Houston

Osama Rahma
Assistant Professor
Dana-Farber Cancer Institute

Paul Rennert
President and Chief Scientific Officer
Aleta Biotherapeutics

Catherine Sabatos-Peyton
Director
Novartis

Beth Trehu
Chief Medical Officer
Jounce Therapeutics

Shanthi Ganesh
Assistant Professor
University of Houston

Weiyi Peng
Assistant Professor
University of Houston

Osama Rahma
Assistant Professor
Dana-Farber Cancer Institute

Mark Yore
Manager of Corporate Development
Jounce Therapeutics

Sarah McWhirter
Director - Sting Program
Aduro Biotech

Mark Poznansky
Director, Vaccine and Immunotherapy Center (VIC), Massachusetts General Hospital (MGH) & Associate Professor
Harvard Medical School

Mark Paris
Director, Translational Applications Biopharma Business Development
Mitra Biotech Inc.

Weiyi Peng
Assistant Professor
University of Houston

Osama Rahma
Assistant Professor
Dana-Farber Cancer Institute

Paul Rennert
President and Chief Scientific Officer
Aleta Biotherapeutics

Catherine Sabatos-Peyton
Director
Novartis

Beth Trehu
Chief Medical Officer
Jounce Therapeutics

Shanthi Ganesh
Assistant Professor
University of Houston

Weiyi Peng
Assistant Professor
University of Houston

Osama Rahma
Assistant Professor
Dana-Farber Cancer Institute

Mark Yore
Manager of Corporate Development
Jounce Therapeutics

Sarah McWhirter
Director - Sting Program
Aduro Biotech

Mark Poznansky
Director, Vaccine and Immunotherapy Center (VIC), Massachusetts General Hospital (MGH) & Associate Professor
Harvard Medical School

Mark Paris
Director, Translational Applications Biopharma Business Development
Mitra Biotech Inc.

Weiyi Peng
Assistant Professor
University of Houston

Osama Rahma
Assistant Professor
Dana-Farber Cancer Institute

Paul Rennert
President and Chief Scientific Officer
Aleta Biotherapeutics

Catherine Sabatos-Peyton
Director
Novartis

Beth Trehu
Chief Medical Officer
Jounce Therapeutics

Shanthi Ganesh
Assistant Professor
University of Houston

Weiyi Peng
Assistant Professor
University of Houston

Osama Rahma
Assistant Professor
Dana-Farber Cancer Institute

Mark Yore
Manager of Corporate Development
Jounce Therapeutics

Sarah McWhirter
Director - Sting Program
Aduro Biotech

Mark Poznansky
Director, Vaccine and Immunotherapy Center (VIC), Massachusetts General Hospital (MGH) & Associate Professor
Harvard Medical School
The path to clinical success begins in the lab. We have seen a lot of molecules struggled through clinical phases due to a lack of preclinical understanding. This workshop will give you the practical skills and insight to help you make informed decisions at the preclinical phase, leading you to more robust and reliable results at the trial stage. Through case studies and group discussions, this interactive session will dive into the following areas, which prime your preclinical understanding prior to the main conference.

Topics that are being covered include:

- A breakdown of the models that are currently available, their relative translatability and where they can be implemented best for both ICIs and IO combinations
- An analysis of the key challenges that are being faced at the preclinical stage and the key developments that will enable us to overcome them
- Look at how you can build a robust scientific rationale at the preclinical stage to drive greater success at the clinical phase

Pre-Clinical Development Challenges in Checkpoint Modulators and IO Combinations

9:00am - 12:00pm

Mithun Khattar
Scientist & Immuno-Oncology Lead
Takeda

Excellent meeting. Great opportunity for discussions between large pharma, small start ups, academia and regulatory authorities

Merck
<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>8.30</td>
<td>Chair’s Opening Remarks</td>
<td>Mark Yore, Manager of Corporate Development, Jounce Therapeutics</td>
</tr>
<tr>
<td>8.40</td>
<td>Navigating the complex ICI-IO landscape – Recent updates and Future Challenges</td>
<td>Paul Rennert, President and Chief Scientific Officer, Aleta Biotherapeutics</td>
</tr>
<tr>
<td>9.10</td>
<td>Establishing a New Set of Biological Goals for Checkpoint Inhibitors and IO Combinations</td>
<td>John M. Burke, Co-Founder, President, and Chief Executive Officer, Applied Biomath</td>
</tr>
<tr>
<td>9.40</td>
<td>Model Aided Drug Invention Case Study: GITR-Mediated T Cell dynamics in Mouse Tumor Micro Environment</td>
<td>Jonathan Zalevsky, Senior Vice President, Research and Chief Scientific Officer, NKTR Therapeutics</td>
</tr>
<tr>
<td>10.10</td>
<td>Speed Networking &amp; Morning Refreshments</td>
<td></td>
</tr>
<tr>
<td>12.00</td>
<td>A Clinically-Predictive Ex-Vivo Tumor Modelling Platform for Drug Discovery and Development</td>
<td></td>
</tr>
</tbody>
</table>
### Lessons Learned from a Clinical Trial Targeting ICOS

- Lessons Learned from a Clinical Trial Targeting ICOS
  - JTX-2011, an ICOS agonist, was evaluated as monotherapy and in combination with nivolumab in the ICONIC trial
  - Responses and tumor reductions observed with monotherapy and combination were associated with a mechanism related pharmacodynamic biomarker
  - Reverse translational analyses enabled by biomarkers have redirected JTX-2011 clinical development strategy

### Overcoming Resistance & Personalizing Combination Therapies

- Targeting the PI3K Pathway to Overcome Immune Resistance
  - Discuss how tumor intrinsic signaling pathways modulate T cell-mediated antitumor immune responses.
  - Identification of the mechanism by which oncogenic activation of the PI3K pathway promotes immune resistance.
  - Development of therapeutic strategies to improve the efficacy of cancer immunotherapy by combining with PI3K inhibition.

### Delineating Myeloid Cell Subsets and Their Role in Response to Cancer Immunotherapy

- Delineating Myeloid Cell Subsets and Their Role in Response to Cancer Immunotherapy
  - Myeloid cell subsets associated with immune suppression and immune activation in cancer.
  - Combination therapies reveal new insights into the pro- and anti-tumor contribution of myeloid cells in cancer.
  - Emerging novel strategies for targeting myeloid cells to enhance cancer immunotherapy.

### Bispecific and Biparatopic Human Heavy Chain Antibodies in Immune Oncology

- Bispecific and Biparatopic Human Heavy Chain Antibodies in Immune Oncology
  - Discuss different formats of T cell engaging bispecific antibodies.
  - Explore biparatopic heavy chain antibodies against CD38.

### STING Pathway Activation Enhances Checkpoint Blockade to Elicit an Anti-Tumor CD8+ T Cell Response in Preclinical Models

- STING Pathway Activation Enhances Checkpoint Blockade to Elicit an Anti-Tumor CD8+ T Cell Response in Preclinical Models
  - Describe the rationale for targeting STING within the tumor microenvironment and the mechanism of optimal STING-induced anti-tumor CD8+ T cell immunity.
  - Highlight how STING activation enhances the therapeutic effect of checkpoint inhibition.
  - Explore the immune correlates associated with the combination of STING agonist-based immunotherapy and checkpoint inhibition.

### T Cell Dysfunction and Combination Immunotherapy

- T Cell Dysfunction and Combination Immunotherapy
  - Single-cell analysis of tumor-infiltrating lymphocytes to probe the mechanisms for combination immunotherapy.
  - PD1/GITR combination immunotherapy led to a synergistic increase in tumor antigen-specific memory precursor effector T cells dependent on availability of the CD226 costimulatory pathway.

### Chair’s Closing Remarks

- Chair’s Closing Remarks
  - Summarize the day’s key takeaways and look forward to future developments in cancer immunotherapy.
**CONFERENCE DAY TWO**

**MARCH 21, 2019**

### 8.30 Chair’s Opening Remarks

**Jeremy Graff**
Chief Scientific Officer
Biothera

### 8.40 Re-Training Innate Immunity: Combining the Novel Beta Glucan, Imprime PGG, with Checkpoint Inhibitors to Drive a Robust, Coordinated Anti-Cancer Immune Response

- Imprime PGG binds directly to cells of the innate immune system driving innate immune cell-mediated tumor killing, re-orienting macrophage polarization and enhancing antigen presentation capacity
- Imprime PGG thereby stimulates T cell-mediated immunity
- Imprime PGG mechanistically complements immune checkpoint inhibitor therapy to trigger a robust anti-cancer immune response

**Raphael Clynes**
Vice President of Translational Biology
Xencor

### 9.10 T Cell Engagers, Checkpoints and Cytokines to Broaden Immune Responses to Cancer

- IO therapy is limited by poor immune recognition, multiple checkpoints and insufficient T cell infiltration
- Xencor’s pipeline is focused on overcoming these obstacles to broaden the reach of IO therapy
- CD3 bispecifics overcomes limited immune recognition by directly activating T cells by targeting common hematologic and solid tumor specific targets (CD20, CD123, SSTR2). Clinical trials and next gen approaches will be discussed
- Bispecific checkpoints clinical trials have been initiated at Xencor (DUET studies) targeting PD1, CTLA4, ICOS and LAG3. Rationale, preclinical antitumor activity and clinical plans/updates will be discussed
- Rationally designed T cell cytokines (IL-15 and others) with T cell targeting and long acting pharmacodynamic preclinical activity will be discussed that potently enhance intratumoral T cell infiltration

**Patrick Holder**
Protein Chemistry Scientist
Genentech

**Catherine Sabatos-Peyton**
Director
Amgen

**Eva Vanamee**
Co-Founder
FusionBio

### 9.40 Panel Discussion: Mind the Gap – Considering New Targets from Biological Rationale to Therapeutic Protein Delivery

- Hear the perspectives from both biological and protein chemistry sides of the discussion
- Hone in on the key areas where each function can support one another in their shared goal of accelerating more clinical relevant IO drugs
- Look at the future targets for ICIs and IO combination therapies and assess their true value

**10.30 Morning Refreshments**
### 11.30 Stromal-Imposed Immunosuppression in the Era of Checkpoint Blockade

- Mesenchymal stromal cells impinge on anti-tumor immunity
- We still lack a full understanding of the cellular and molecular mechanisms by which stromal-imposed immunosuppression is exerted
- We have identified a discrete population of FAP+ stromal cells in immune-excluded breast cancers with potent immunomodulatory potential

**Viviana Cremasco**, Investigator, **Novartis**

### 11.30 Immuneogenicity of I-O Therapeutics: The Good and The Bad

- I-O therapeutic depended on manipulating immune checkpoints, one consequence of this is an a decreased tolerance including the therapeutic
- Is it possible that the MOA of I-O therapeutics contribute to immunogenicity to these therapeutics
- Are I-O combination therapies increasing immunogenicity and are there strategies to screen for this preclinical
- Strategies to mitigate immunogenicity to I-O therapeutics

**Jochem Gokemeijer**, Associate Director, **Bristol-Myers Squibb**

### 12.00 Panel Discussion: Reviewing the Future Challenges in Tumor Modeling for IO Combinations

- Review the current models and preclinical tools that are available and assess their true value in getting the results that predicate clinical successes and failures
- Identify the weak spots in current development strategies and discuss how these can be fixed

**Mithun Khattar**, Scientist & Immuno-Oncology Lead, **Takeda**

**Viviana Cremasco**, Investigator, **Novartis**

### 12.00 Panel Discussion: What Are the Solutions to The These Immunogenicity Challenges

- Consider a framework by which the effects of specific IO combos can be predicted, based on what was learnt in the talks prior
- Discuss trends that were seen between the previous presentations to solve their respective challenges
- Look at combining the capabilities of pharma and academia to solve these problems

**Osama Rahma**, Assistant Professor, **Dana-Farber**

**Jochem Gokemeijer**, Associate Director, **Bristol-Myers Squibb**

### 12.45 Lunch

**Mark Poznansky**
Director, Vaccine and Immunotherapy Center (VIC), Massachusetts General Hospital (MGH) & Associate Professor, Harvard Medical School

### 13.45 Development of novel combination immunotherapies for ovarian cancer and mesothelioma

- Description of novel products developed at VIC and their preclinical development
- Description of novel computational approaches to guide and predict immunotherapeutic targeting and responsiveness
- Description of path to first in human studies for novel combinations

**Hans Van Eenemann**
Executive Vice President Antibody Research and Site Head, **Aduro Biotech**

### 14.15 Targeting the Innate CD47-SIRP\(\alpha\) Checkpoint Using Pan-Allele SIRP\(\alpha\) Blocking Antibodies

- Unique pan-allele SIRP\(\alpha\) blocking antibody
- SIRP\(\alpha\) blocking differentiates from CD47 targeting
- SIRP\(\alpha\) blocking enhances PD-1/PDL1 blocking in vivo

**Paul Moore**
Vice President, **Macrogenics**

### 14.45 PD-1-Based Bispecific Antibody Therapies

- Analyzing anti-drug-antibody (ADA) responses and the integrity of your bispecific format is of paramount importance in the preclinical and clinical development of any bispecific antibody.
- The selection of the right bioanalytical tools is a key consideration of this process

**15.15 Chair’s Closing Remarks**
Personalis, Inc. provides genomic solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. Our patented ACE Technology improves every step in the sequencing process, from nucleic acid extraction, to sequencing, to data analytics. This delivers augmented coverage of difficult-to-sequence genomic regions that are missed with conventional sequencing techniques. This comprehensive approach provides data of the highest quality to enable the rational design and development of effective cancer immunotherapies.

www.personalis.com

Crown Bioscience is a global drug discovery and development solutions company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research.

www.crownbio.com

Caprion Biosciences is a specialty laboratory CRO with an established track record in biomarkers, bioanalytical and immune monitoring services. Through its advanced immune monitoring platform, Caprion supports the development of vaccine and immunotherapy programs that require the characterization of innate and adaptive immunity.

www.caprion.com

Immudex manufactures MHC Dextramers, the leading MHC multimer reagent for the detection of antigen-specific T cells. Under an agreement with the US Cancer Immunotherapy Consortium (CIC) and the European Cancer Immunotherapy Consortium (CIMT), Immudex also provides MHC Multimer and Elispot proficiency panel services worldwide.

www.immudex.com

Mitra Biotech is a global leader in advancing personalized cancer treatment and empowering drug development & discovery. Our phenotypic CANscript platform delivers powerful insight for our biopharma partners. Because CANscript conserves the native tumor microenvironment and delivers 1:1 clinical correlation, it can be used to predict response of an indication to a specific drug (or drug combination), or to better understand MOA of a given compound.

www.mitrabio.com

Applied BioMath uses mathematical modeling and simulation to provide quantitative and predictive guidance to biotechnology and pharmaceutical companies to help accelerate and de-risk drug research and development. Their Model-Aided Drug Invention (MADI) approach employs proprietary algorithms and software to support groups worldwide in decision-making from early research through clinical trials.

www.appliedbiomath.com

Mitra Biotech

Expertise Partner

Mitra Biotech is a global leader in advancing personalized cancer treatment and empowering drug development & discovery. Our phenotypic CANscript platform delivers powerful insight for our biopharma partners. Because CANscript conserves the native tumor microenvironment and delivers 1:1 clinical correlation, it can be used to predict response of an indication to a specific drug (or drug combination), or to better understand MOA of a given compound.

www.mitrabio.com

Applied BioMath

Expertise Partner

Applied BioMath uses mathematical modeling and simulation to provide quantitative and predictive guidance to biotechnology and pharmaceutical companies to help accelerate and de-risk drug research and development. Their Model-Aided Drug Invention (MADI) approach employs proprietary algorithms and software to support groups worldwide in decision-making from early research through clinical trials.

www.appliedbiomath.com

Crown Bioscience

Event Partner

Crown Bioscience is a global drug discovery and development solutions company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research.

www.crownbio.com

Caprion Biosciences

Exhibitor

Caprion Biosciences is a specialty laboratory CRO with an established track record in biomarkers, bioanalytical and immune monitoring services. Through its advanced immune monitoring platform, Caprion supports the development of vaccine and immunotherapy programs that require the characterization of innate and adaptive immunity.

www.caprion.com

Immudex

Exhibitor

Immudex manufactures MHC Dextramers, the leading MHC multimer reagent for the detection of antigen-specific T cells. Under an agreement with the US Cancer Immunotherapy Consortium (CIC) and the European Cancer Immunotherapy Consortium (CIMT), Immudex also provides MHC Multimer and Elispot proficiency panel services worldwide.

www.immudex.com

Denvor Oorloff

Partnerships Director

Tel: +44 (0)203 141 8748

Email: denvor.oorloff@hansonwade.com

GET INVOLVED
Gain knowledge that will optimize your rationale when selecting Checkpoint Modulators and Combination Partners, to find the right combination sooner

Optimize your development process to advance your combination pipeline

Overcome the key roadblocks that prevent Checkpoint Modulator containing combinations from reaching the market

Team Discounts*
- 10% discount – 3 delegates
- 15% discount – 4 delegates
- 20% discount – 5 or more delegates

Please note that discounts are only valid when three or more delegates from one company book and pay at the same time.

Contact: register@hansonwade.com

Data Protection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: Database Manager, Hanson Wade, Suite A, 6 Honduras Street, London EC1Y 0TH

TERMS & CONDITIONS

Full payment is due on registration. Cancellation and Substitution Policy:

Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organization can be made at any time.

Changes to Conference & Agenda: Hanson Wade reserves the right to postpone or cancel an event, to change the location or alter the advertised speakers. Hanson Wade is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including, without limitation, acts of God, natural disasters, sabotage, accident, strike or industrial disputes, terrorism or hostilities.

Data Protection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: Database Manager, Hanson Wade, Suite A, 6 Honduras Street, London EC1Y 0TH

Terms and Conditions: Full payment is due on registration. Cancellation and substitution policy:

Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organization can be made at any time.

Changes to Conference & Agenda: Hanson Wade reserves the right to postpone or cancel an event, to change the location or alter the advertised speakers. Hanson Wade is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including, without limitation, acts of God, natural disasters, sabotage, accident, strike or industrial disputes, terrorism or hostilities.

Data Protection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: Database Manager, Hanson Wade, Suite A, 6 Honduras Street, London EC1Y 0TH

Solution Provider Pricing

<table>
<thead>
<tr>
<th>Standard Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Conference + Workshop</td>
</tr>
<tr>
<td>Conference Only</td>
</tr>
<tr>
<td>Workshops (Each)</td>
</tr>
</tbody>
</table>

Drug Developer Pricing

<table>
<thead>
<tr>
<th>Standard Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Conference + Workshop</td>
</tr>
<tr>
<td>Conference Only</td>
</tr>
<tr>
<td>Workshops (Each)</td>
</tr>
</tbody>
</table>

Team Discounts*

- 10% discount – 3 delegates
- 15% discount – 4 delegates
- 20% discount – 5 or more delegates

Please note that discounts are only valid when three or more delegates from one company book and pay at the same time.

Contact: register@hansonwade.com

Data Protection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: Database Manager, Hanson Wade, Suite A, 6 Honduras Street, London EC1Y 0TH

TERMS & CONDITIONS

Full payment is due on registration. Cancellation and Substitution Policy:

Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organization can be made at any time.

Changes to Conference & Agenda: Hanson Wade reserves the right to postpone or cancel an event, to change the location or alter the advertised speakers. Hanson Wade is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including, without limitation, acts of God, natural disasters, sabotage, accident, strike or industrial disputes, terrorism or hostilities.

Data Protection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: Database Manager, Hanson Wade, Suite A, 6 Honduras Street, London EC1Y 0TH

Solution Provider Pricing

<table>
<thead>
<tr>
<th>Standard Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Conference + Workshop</td>
</tr>
<tr>
<td>Conference Only</td>
</tr>
<tr>
<td>Workshops (Each)</td>
</tr>
</tbody>
</table>

Drug Developer Pricing

<table>
<thead>
<tr>
<th>Standard Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Conference + Workshop</td>
</tr>
<tr>
<td>Conference Only</td>
</tr>
<tr>
<td>Workshops (Each)</td>
</tr>
</tbody>
</table>